Institution
Indiana University
Education•Bloomington, Indiana, United States•
About: Indiana University is a education organization based out in Bloomington, Indiana, United States. It is known for research contribution in the topics: Population & Poison control. The organization has 64480 authors who have published 150058 publications receiving 6392902 citations. The organization is also known as: Indiana University system & indiana.edu.
Topics: Population, Poison control, Context (language use), Health care, Cancer
Papers published on a yearly basis
Papers
More filters
••
University of Tokyo1, Boston University2, Brookhaven National Laboratory3, University of California, Irvine4, California State University, Dominguez Hills5, Chonnam National University6, Duke University7, George Mason University8, Gifu University9, Indiana University10, University of Tsukuba11, Okayama University12, Kobe University13, Kyoto University14, Los Alamos National Laboratory15, Louisiana State University16, University of Maryland, College Park17, University of Minnesota18, Miyagi University of Education19, Stony Brook University20, Nagoya University21, Niigata University22, Osaka University23, Seoul National University24, Shizuoka University25, Sungkyunkwan University26, Tohoku University27, Tokai University28, Tokyo Institute of Technology29, University of Warsaw30, University of Washington31
TL;DR: In this article, a combined analysis of fully-contained, partially-contained and upward-going muon atmospheric neutrino data from a 1489 d exposure of the Super-Kamiokande detector is presented.
Abstract: We present a combined analysis of fully-contained, partially-contained and upward-going muon atmospheric neutrino data from a 1489 d exposure of the Super-Kamiokande detector. The data samples span roughly five decades in neutrino energy, from 100 MeV to 10 TeV. A detailed Monte Carlo comparison is described and presented. The data is fit to the Monte Carlo expectation, and is found to be consistent with neutrino oscillations of {nu}{sub {mu}}{r_reversible}{nu}{sub {tau}} with sin{sup 2}2{theta}>0.92 and 1.5x10{sup -3}<{delta}m{sup 2}<3.4x10{sup -3} eV{sup 2} at 90% confidence level.
701 citations
••
TL;DR: It is shown that Notch and Delta can associate within the membrane of a single cell, and further, that they form detergent-soluble intermolecular complexes.
701 citations
••
TL;DR: It is shown that phosphorylation of an enzyme involved in the ubiquitylation cascade (Nedd4‐2) controls cell surface density of ENaC and a paradigm for the control of ion channels is proposed.
Abstract: The epithelial Na+ channel (ENaC) plays an essential role in the regulation of whole body Na+ balance and blood pressure. The cell surface expression of this channel, a complex of three subunits (α, β and γENaC), has been shown to be regulated by hormones such as aldosterone and vasopressin and by intracellular signaling, including ubiquitylation and/or phosphorylation. However, the molecular mechanisms involving phosphorylation in the regulation of ENaC are unclear. Here we show by expression studies in Xenopus laevis oocytes that the aldosterone-induced Sgk1 kinase interacts with the ubiquitin protein ligase Nedd4-2 in a PY motif-dependent manner and phosphorylates Nedd4-2 on Ser444 and, to a lesser extent, Ser338. Such phosphorylation reduces the interaction between Nedd4-2 and ENaC, leading to elevated ENaC cell surface expression. These data show that phosphorylation of an enzyme involved in the ubiquitylation cascade (Nedd4-2) controls cell surface density of ENaC and propose a paradigm for the control of ion channels. Moreover, they suggest a novel and complete signaling cascade for aldosterone-dependent regulation of ENaC.
700 citations
••
University of Utah1, University of Michigan2, The Royal Marsden NHS Foundation Trust3, Ohio State University4, Indiana University5, St. Jude Medical Center6, University of Queensland7, Beaumont Hospital8, BC Cancer Agency9, University of Rochester10, Harvard University11, American Society of Clinical Oncology12, National Institutes of Health13, Baylor College of Medicine14, Sungkyunkwan University15, University of the West of England16, Tohoku University17, Radboud University Nijmegen18, University of Toronto19, Saint Joseph Mercy Health System20, Mayo Clinic21, University of Washington22, Memorial Hospital of South Bend23, University of Texas at Austin24, Johns Hopkins University25
TL;DR: An international Expert Panel that conducted a systematic review and evaluation of the literature and developed recommendations for optimal IHC ER/PgR testing performance recommended that ER and PgR status be determined on all invasive breast cancers and breast cancer recurrences.
Abstract: Purpose To develop a guideline to improve the accuracy of immunohistochemical (IHC) estrogen receptor (ER) and progesterone receptor (PgR) testing in breast cancer and the utility of these receptors as predictive markers. Methods The American Society of Clinical Oncology and the College of American Pathologists convened an international Expert Panel that conducted a systematic review and evaluation of the literature in partnership with Cancer Care Ontario and developed recommendations for optimal IHC ER/PgR testing performance. Results Up to 20% of current IHC determinations of ER and PgR testing worldwide may be inaccurate (false negative or false positive). Most of the issues with testing have occurred because of variation in pre-analytic variables, thresholds for positivity, and interpretation criteria. Recommendations The Panel recommends that ER and PgR status be determined on all invasive breast cancers and breast cancer recurrences. A testing algorithm that relies on accurate, reproducible assay performance is proposed. Elements to reliably reduce assay variation are specified. It is recommended that ER and PgR assays be considered positive if there are at least 1% positive tumor nuclei in the sample on testing in the presence of expected reactivity of internal (normal epithelial elements) and external controls. The absence of benefit from endocrine therapy for women with ER-negative invasive breast cancers has been confirmed in large overviews of randomized clinical trials.
700 citations
••
Cleveland Clinic Lerner College of Medicine1, University of Minnesota2, Stanford University3, Centre for Addiction and Mental Health4, Mayo Clinic5, University of Montana6, Children's Mercy Hospital7, Veterans Health Administration8, Indiana University9, Icahn School of Medicine at Mount Sinai10, St. Jude Children's Research Hospital11
TL;DR: Evidence from the published literature supporting associations between CYP2D6 and CYC19 polymorphisms and SSRIs efficacy and safety is summarized and dosing recommendations for fluvoxamine, paroxetine, citalopram, escitaloprams, and sertraline based on CYP1C19 genotype are provided.
Abstract: Selective serotonin reuptake inhibitors (SSRIs) are primary treatment options for major depressive and anxiety disorders. CYP2D6 and CYP2C19 polymorphisms can influence the metabolism of SSRIs, thereby affecting drug efficacy and safety. We summarize evidence from the published literature supporting these associations and provide dosing recommendations for fluvoxamine, paroxetine, citalopram, escitalopram, and sertraline based on CYP2D6 and/or CYP2C19 genotype (updates at www.pharmgkb.org).
700 citations
Authors
Showing all 64884 results
Name | H-index | Papers | Citations |
---|---|---|---|
Frank B. Hu | 250 | 1675 | 253464 |
Stuart H. Orkin | 186 | 715 | 112182 |
Bruce M. Spiegelman | 179 | 434 | 158009 |
David R. Williams | 178 | 2034 | 138789 |
D. M. Strom | 176 | 3167 | 194314 |
Markus Antonietti | 176 | 1068 | 127235 |
Lei Jiang | 170 | 2244 | 135205 |
Brenda W.J.H. Penninx | 170 | 1139 | 119082 |
Nahum Sonenberg | 167 | 647 | 104053 |
Carl W. Cotman | 165 | 809 | 105323 |
Yang Yang | 164 | 2704 | 144071 |
Jaakko Kaprio | 163 | 1532 | 126320 |
Ralph A. DeFronzo | 160 | 759 | 132993 |
Gavin Davies | 159 | 2036 | 149835 |
Tyler Jacks | 158 | 463 | 115172 |